Therapeutic antibodies for the treatment of pancreatic cancer

TheScientificWorldJournal

Volumn 10, Issue , 2010, Pages 1107-1120

  Chames, Patrick ^a   Kerfelec, Brigitte ^a   Baty, Daniel ^a  

^a INSERM   (France)

Author keywords

Antibodies; Bispecific; Clinical trials; Pancreatic; Therapy

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; ARZERRA; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CATUMAXOMAB; CETUXIMAB; CIXUTUMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; IBRITOMOMAB; IBRITUMOMAB TIUXETAN; INTEGRIN; INTEGRIN ALPHA 5 BETA 1; KAB201; MATUZUMAB; MESOTHELIN; MORAB 009; OFATUMUMAB; PANITUMUMAB; PLACEBO; REMOVAB; RITUXIMAB; SOMATOMEDIN C RECEPTOR; SS1P; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VECTIBIS; VOLOCIXIMAB; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASCITES; BLOOD TOXICITY; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LEUKOCYTE COUNT; LEUKOPENIA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; MORTALITY; MOUSE; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROTEIN EXPRESSION; RASH; RECTUM CANCER; REVIEW; SIDE EFFECT; SKIN TOXICITY; SURVIVAL RATE; WEIGHT REDUCTION; ANIMAL; DRUG SCREENING; PANCREAS TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; PANCREATIC NEOPLASMS;

EID: 77955860777     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2010.103     Document Type: Review

References (86)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M.J. (2009) Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249.
2. Klapman, J. and Malafa, M.P. (2008) Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 15, 280-287.
3. Helm, J.F., Centeno, B.A., Coppola, D., Druta, M., Park, J.Y., Chen, D.T., et al. (2008) Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control 15, 288-294.
4. Burris, H.A., 3rd, Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413.
5. Cartwright, T., Richards, D.A., and Boehm, K.A. (2008) Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network. Cancer Control 15, 308-313.
6. Nieto, J., Grossbard, M.L., and Kozuch, P. (2008) Metastatic pancreatic cancer 2008: is the glass less empty? Oncologist 13, 562-576.
7. Heinemann, V., Philip, P.A., and Pelzer, U. (2009) Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointest. Cancer Res. 3, S43-47.
8. Moore, M.J., Goldstein, D., Hamm, J., Figer, A., Hecht, J.R., Gallinger, S., et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966.
9. Senderowicz, A.M., Johnson, J.R., Sridhara, R., Zimmerman, P., Justice, R., and Pazdur, R. (2007) Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas. Oncology (Williston Park) 21, 1696-1706; discussion 1706-1709, 1712, 1715.
10. Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001) Stem cells, cancer, and cancer stem cells. Nature 414, 105-111.
11. Visvader, J.E. and Lindeman, G.J. (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768.
12. Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., et al. (2007) Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037.
13. Simeone, D.M. (2008) Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin. Cancer Res. 14, 5646-5648.
14. Hwang, R.F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K.D., Rivera, A., et al. (2008) Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918-926.
15. Hernandez-Munoz, I., Skoudy, A., Real, F.X., and Navarro, P. (2008) Pancreatic ductal adenocarcinoma: cellular origin, signaling pathways and stroma contribution. Pancreatology 8, 462-469.
16. Saif, M.W., Podoltsev, N.A., Rubin, M.S., Figueroa, J.A., Lee, M.Y., Kwon, J., et al. (2010) Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer. Cancer Invest. 28, 186-194.
17. Chames, P., Van Regenmortel, M., Weiss, E., and Baty, D. (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br. J. Pharmacol. 157, 220-233.
18. Chames, P. and Baty, D. (2009) Bispecific antibodies for cancer therapy. Curr. Opin. Drug Discov. Dev. 12, 276-283.
19. Chames, P. and Baty, D. (2009) Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 1, 539-547.
20. Xie, K., Wei, D., and Huang, S. (2006) Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev. 17, 147-156.
21. Tabernero, J. (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res. 5, 203-220.
22. Niedergethmann, M., Hildenbrand, R., Wostbrock, B., Hartel, M., Sturm, J.W., Richter, A., et al. (2002) High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25, 122-129.
23. Holloway, S.E., Beck, A.W., Shivakumar, L., Shih, J., Fleming, J.B., and Brekken, R.A. (2006) Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. Ann. Surg. Oncol. 13, 1145-1155.
24. Kindler, H.L., Friberg, G., Singh, D.A., Locker, G., Nattam, S., Kozloff, M., et al. (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23, 8033-8040. (Pubitemid 46657405)
25. Kindler, H.L., Niedzwiecki, D., Hollis, D., Oraefo, E., Schrag, D., Hurwitz, H., et al. (2007) A double-blind, placebocontrolled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J. Clin. Oncol. 25(18S), Abstract 4508.
26. Van Cutsem, E., Vervenne, W.L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.L., et al. (2009) Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J. Clin. Oncol. 27, 2231-2237.
27. Ricart, A.D., Tolcher, A.W., Liu, G., Holen, K., Schwartz, G., Albertini, M., et al. (2008) Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study. Clin. Cancer Res. 14, 7924-7929.
28. Ramakrishnan, V., Bhaskar, V., Law, D.A., Wong, M.H., DuBridge, R.B., Breinberg, D., et al. (2006) Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J. Exp. Ther. Oncol. 5, 273-286.
29. Fjallskog, M.L., Lejonklou, M.H., Oberg, K.E., Eriksson, B.K., and Janson, E.T. (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin. Cancer Res. 9, 1469-1473.
30. Tobita, K., Kijima, H., Dowaki, S., Kashiwagi, H., Ohtani, Y., Oida, Y., et al. (2003) Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int. J. Mol. Med. 11, 305-309.
31. Xiong, H.Q., Rosenberg, A., LoBuglio, A., Schmidt, W., Wolff, R.A., Deutsch, J., et al. (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J. Clin. Oncol. 22, 2610-2616.
32. Philips, P.A., Benedetti, J., Fenoglio-Preiser, C., Zalupski, M., Lenz, H., O'Reilly, E., et al. (2007) Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J. Clin. Oncol. 25, 4509.
33. Burtness, B.A., Powell, M.E., Berlin, J.D., Liles, D.K., Chapman, A.E., Mitchell, E.P., et al. (2008) Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: updated survival and CA19-9 results. J. Clin. Oncol. 26(15S), Abstract 4642.
34. Graeven, U., Kremer, B., Sudhoff, T., Killing, B., Rojo, F., Weber, D., et al. (2006) Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br. J. Cancer 94, 1293-1299.
35. Yang, X.D., Jia, X.C., Corvalan, J.R., Wang, P., Davis, C.G., and Jakobovits, A. (1999) Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236-1243.
36. Safran, H., Steinhoff, M., Mangray, S., Rathore, R., King, T.C., Chai, L., et al. (2001) Overexpression of the HER- 2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. 24, 496-499.
37. Garnock-Jones, K.P., Keating, G.M., and Scott, L.J. (2010) Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 70, 215-239.
38. Safran, H., Iannitti, D., Ramanathan, R., Schwartz, J.D., Steinhoff, M., Nauman, C., et al. (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 22, 706-712.
39. Mihaljevic, A., Buchler, P., Harder, J., Hofheinz, R., Gregor, M., Kanzler, S., et al. (2009) A prospective, nonrandomized phase II trial of trastuzumab and capecitabine in patients with HER2 expressing metastasized pancreatic cancer. BMC Surg. 9, 1.
40. Larbouret, C., Robert, B., Bascoul-Mollevi, C., Penault-Llorca, F., Ho-Pun-Cheung, A., Morisseau, S., et al. (2010) Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. Ann. Oncol. 21, 98-103.
41. Chang, K. and Pastan, I. (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. U. S. A. 93, 136-140.
42. Hassan, R. and Ho, M. (2008) Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44, 46-53.
43. Argani, P., Iacobuzio-Donahue, C., Ryu, B., Rosty, C., Goggins, M., Wilentz, R.E., et al. (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7, 3862-3868.
44. Hassan, R., Laszik, Z.G., Lerner, M., Raffeld, M., Postier, R., and Brackett, D. (2005) Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am. J. Clin. Pathol. 124, 838-845.
45. Swierczynski, S.L., Maitra, A., Abraham, S.C., Iacobuzio-Donahue, C.A., Ashfaq, R., Cameron, J.L., et al. (2004) Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum. Pathol. 35, 357-366.
46. Hassan, R., Bera, T., and Pastan, I. (2004) Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 10, 3937-3942.
47. Hassan, R., Bullock, S., Premkumar, A., Kreitman, R.J., Kindler, H., Willingham, M.C., et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelinexpressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res. 13, 5144-5149.
48. Hassan, R., Ebel, W., Routhier, E.L., Patel, R., Kline, J.B., Zhang, J., et al. (2007) Preclinical evaluation of MORAb- 009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 7, 20.
49. Laheru, D.A., Cohen, S.J., Phillips, M., Armstrong, D.K., et al. (2008) A phase I study of MORab-009, a monoclonal antibody against mesothelin, in mesothelioma, pancreatic and ovarian cancer. J. Clin. Oncol. 26(15S), Abstract 3578.
50. Yamaguchi, K., Enjoji, M., and Tsuneyoshi, M. (1991) Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J. Surg. Oncol. 47, 148-154.
51. Blumenthal, R.D., Hansen, H.J., and Goldenberg, D.M. (2005) Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res. 65, 8809-8817.
52. Sultana, A., Shore, S., Raraty, M.G., Vinjamuri, S., Evans, J.E., Smith, C.T., et al. (2009) Randomised phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I(131) KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma. BMC Cancer 9, 66.
53. Rowinsky, E.K., Youssoufian, H., Tonra, J.R., Solomon, P., Burtrum, D., and Ludwig, D.L. (2007) IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 13, 5549s-5555s.
54. Burtrum, D., Zhu, Z., Lu, D., Anderson, D.M., Prewett, M., Pereira, D.S., et al. (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63, 8912-8921.
55. Beltran, P.J., Mitchell, P., Chung, Y.A., Cajulis, E., Lu, J., Belmontes, B., et al. (2009) AMG 479, a fully human antiinsulin- like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. [Epub ahead of print]
56. Oikawa, S., Sugiyama, M., Kuroki, M., and Nakazato, H. (2000) Extracellular N-domain alone can mediate specific heterophilic adhesion between members of the carcinoembryonic antigen family, CEACAM6 and CEACAM8. Biochem. Biophys. Res. Commun. 278, 564-568.
57. Scholzel, S., Zimmermann, W., Schwarzkopf, G., Grunert, F., Rogaczewski, B., and Thompson. J. (2000) Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and oppositely deregulated in hyperplastic colorectal polyps and early adenomas. Am. J. Pathol. 156, 595-605.
58. Han, H., Bearss, D.J., Browne, L.W., Calaluce, R., Nagle, R.B., and Von Hoff, D.D. (2002) Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62, 2890-2896.
59. Ryu, B., Jones, J., Blades, N.J., Parmigiani, G., Hollingsworth, M.A., Hruban, R.H., et al. (2002) Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 62, 819-826.
60. Iacobuzio-Donahue, C.A., Ashfaq, R., Maitra, A., Adsay, N.V., Shen-Ong, G.L., Berg, K., et al. (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63, 8614-8622.
61. Iacobuzio-Donahue, C.A., Maitra, A., Olsen, M., Lowe, A.W., van Heek, N.T., Rosty, C., et al. (2003) Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 162, 1151-1162.
62. Strickland, L.A., Ross, J., Williams, S., Ross, S., Romero, M., Spencer, S., et al. (2009) Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J. Pathol. 218, 380-390.
63. Riley, C.J., Engelhardt, K.P., Saldanha, J.W., Qi, W., Cooke, L.S., Zhu, Y., et al. (2009) Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res. 69, 1933-1940.
64. Ordonez, C., Screaton, R.A., Ilantzis, C., and Stanners, C.P. (2000) Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 60, 3419-3424.
65. Baeuerle, P.A. and Gires, O. (2007) EpCAM (CD326) finding its role in cancer. Br. J. Cancer 96, 417-423.
66. Gires, O., Klein, C.A., and Baeuerle, P.A. (2009) On the abundance of EpCAM on cancer stem cells. Nat. Rev. Cancer 9, 143; author reply.
67. Maetzel, D., Denzel, S., Mack, B., Canis, M., Went, P., Benk, M., et al. (2009) Nuclear signalling by tumourassociated antigen EpCAM. Nat. Cell Biol. 11, 162-171.
68. Linke, R., Klein, A., and Seimetz, D. (2010) Catumaxomab: clinical development and future directions. MAbs. 2. [Epub ahead of print]
69. Burges, A., Wimberger, P., Kumper, C., Gorbounova, V., Sommer, H., Schmalfeldt, B., et al. (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin. Cancer Res. 13, 3899-3905.
70. Strohlein, M.A., Siegel, R., Jager, M., Lindhofer, H., Jauch, K.W., and Heiss, M.M. (2009) Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J. Exp. Clin. Cancer Res. 28, 18.
71. Haas, C., Krinner, E., Brischwein, K., Hoffmann, P., Lutterbuse, R., Schlereth, B., et al. (2009) Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology 214, 441-453.
72. Brischwein, K., Schlereth, B., Guller, B., Steiger, C., Wolf, A., Lutterbuese, R., et al. (2006) MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Mol. Immunol. 43, 1129-1143.
73. Salnikov, A.V., Groth, A., Apel, A., Kallifatidis, G., Beckermann, B.M., Khamidjanov, A., et al. (2009) Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J. Cell. Mol. Med. 13, 4023-4033.
74. Gold, D.V., Karanjawala, Z., Modrak, D.E., Goldenberg, D.M., and Hruban, R.H. (2007) PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin. Cancer Res. 13, 7380-7387.
75. Gold, D.V., Alisauskas, R., and Sharkey, R.M. (1995) Targeting of xenografted pancreatic cancer with a new monoclonal antibody, PAM4. Cancer Res. 55, 1105-1110.
76. Gold, D.V., Goldenberg, D.M., Karacay, H., Rossi, E.A., Chang, C.H., Cardillo, T.M., et al. (2008) A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma. Cancer Res. 68, 4819-4826.
77. Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., et al. (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat. Med. 7, 954-960.
78. DeRosier, L.C., Huang, Z.Q., Sellers, J.C., Buchsbaum, D.J., and Vickers, S.M. (2006) Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo. J. Gastrointest. Surg. 10, 1291-1300; discussion 300.
79. DeRosier, L.C., Buchsbaum, D.J., Oliver, P.G., Huang, Z.Q., Sellers, J.C., Grizzle, W.E., et al. (2007) Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin. Cancer Res. 13, 5535s-5543s.
80. Derosier, L.C., Vickers, S.M., Zinn, K.R., Huang, Z., Wang, W., Grizzle, W.E., et al. (2007) TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol. Cancer Ther. 6, 3198-3207.
81. Forero-Torres, A., Shah, J., Wood, T., Posey, J., Carlisle, R., Copigneaux, C., et al. (2010) Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biother. Radiopharm. 25, 13-19.
82. Kaplan-Lefko, P.J., Graves, J.D., Zoog, S.J., Pan, Y., Wall, J., Branstetter, D.G., et al. (2010) Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol. Ther. 9. [Epub ahead of print]
83. Nichols, L.S., Ashfaq, R., and Iacobuzio-Donahue, C.A. (2004) Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am. J. Clin. Pathol. 121, 226-230.
84. Suzuki, M., Kato-Nakano, M., Kawamoto, S., Furuya, A., Abe, Y., Misaka, H., et al. (2009) Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers. Cancer Sci. 100, 1623-1630.
85. Benkoel, L., Bernard, J.P., Payan-Defais, M.J., Crescence, L., Franceschi, C., Delmas, M., et al. (2009) Monoclonal antibody 16D10 to the COOH-terminal domain of the feto-acinar pancreatic protein targets pancreatic neoplastic tissues. Mol. Cancer Ther. 8, 282-291.
86. Panicot-Dubois, L., Aubert, M., Franceschi, C., Mas, E., Silvy, F., Crotte, C., et al. (2004) Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts. Neoplasia 6, 713-724.